Lee:Literature PK/PD/PGx: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
No edit summary |
(→PK/PD) |
||
(7 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
{{Lee_lab}} | |||
{|cellspacing="5" cellpadding="10" style="background:#3674C2; width: 1000px;" | |||
|-valign="top" | |||
|style="background:#ffffff"| | |||
<font color=green> Feel free to add articles ...</font> | <font color=green> Feel free to add articles ...</font> | ||
<!-- Replace the PubMed ID's ("pmid=#######") below with the PubMed ID's for your publications. You can add or remove lines as needed --> | <!-- Replace the PubMed ID's ("pmid=#######") below with the PubMed ID's for your publications. You can add or remove lines as needed --> | ||
==Classic PK/PD papers== | |||
# Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):227-79. Epub 2006 Jan 11. Review.PMID: 16404503 | |||
# Sharma A, Jusko WJ. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol. 1998 Mar;45(3):229-39. Review.PMID: 9517366 | |||
# Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther. 1994 Oct;56(4):406-19.PMID: 7955802 | |||
# Holford NH, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther. 1982;16(2):143-66. Review. No abstract available. PMID: 6752972 | |||
==PK/PD== | ==PK/PD== | ||
# Rajman I. PK/PD modelling and simulations: utility in drug development. Drug Discov Today. 2008 Apr;13(7-8):341-6. Epub 2008 Mar 7. Review.PMID: 18405847 | |||
# | # Mager DE, Jusko WJ. Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2008 Jun;83(6):909-12. Epub 2008 Mar 26. Review.PMID: 18388873 | ||
# | # Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci. 2008 Apr;29(4):186-91. Epub 2008 Mar 18. Review.PMID: 18353445 | ||
# | # Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos. 2003 May;31(5):510-8. Review.PMID: 12695336 | ||
==PGx== | ==PGx== | ||
# Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W, Lenz HJ. Thymidylate synthase gene variations: predictive and prognostic markers. Mol Cancer Ther. 2009 Apr 21 PMID: 19383851 | |||
# | # Strimpakos AS, Syrigos KN, Saif MW. Pharmacogenetics and biomarkers in colorectal cancer. Pharmacogenomics J. 2009 Jun;9(3):147-60. Epub 2009 Apr 21. Review.PMID: 19381163 | ||
# Bhushan S, McLeod H, Walko CM. Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. Clin Colorectal Cancer. 2009 Jan;8(1):15-21. Review.PMID: 19203892 | |||
#3 | # Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009 Jan-Feb;59(1):42-55. Review.PMID: 19147868 | ||
# | # McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009 Jan;8(1):10-6. Review.PMID: 19139108 | ||
# | # Burczynski ME. Pharmacogenomic approaches in clinical studies to identify biomarkers of safety and efficacy. Toxicol Lett. 2009 Apr 10;186(1):18-21. Epub 2008 Oct 31. Review.PMID: 19022363 | ||
#6 | # Roses AD. Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov. 2008 Oct;7(10):807-17. Epub 2008 Sep 19. Review.PMID: 18806753 | ||
# | # van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat. 2008 Jun;11(3):77-98. Epub 2008 May 19. Review.PMID: 18486526 | ||
# Katz DA, Murray B, Bhathena A, Sahelijo L. Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy. Nat Rev Drug Discov. 2008 Apr;7(4):293-305.PMID: 18382463 | |||
#10 | |||
#11 | |||
Latest revision as of 21:09, 19 January 2011
Feel free to add articles ... Classic PK/PD papers
PK/PD
PGx
|